GlobeNewswire
Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
📊
AI Sentiment
Positive
7/10
Aclaris Therapeutics Inc. News
Latest updates and market news for ACRS
3 news
Mar 18 - Mar 24, 2026
Page 1
MT Newswires
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Potential Dermatitis Treatment
📊
AI Sentiment
Positive
6/10
GlobeNewswire
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
📊
AI Sentiment
Positive
7/10
Share this news page